Armed with a novel approach for resolving inflammation and expertise ranging from drug discovery through FDA approval, we merge future-focused intention with data-driven innovation.
We have earned our reputation by developing Vyleesi® (bremelanotide injection), a novel treatment for women with generalized hypoactive sexual desire disorder (HSDD). We are determined to leverage our unique insight into the industry and the melanocortin system to develop groundbreaking therapeutics for inflammatory and autoimmune diseases, with a focus on ocular conditions.
Our management exemplifies the powerful combination of science and business. We support a fast-paced, efficient, nimble, and collaborative working environment that focuses on developing innovative treatments that work with the melanocortin system.
Board of Directors
Carl Spana, PhD
John K.A. Prendergast, PhD
Robert K. deVeer, Jr
J. Stanley Hull
Alan W. Dunton, MD
Arlene M. Morris
Anthony M. Manning, PhD
SCIENTIFIC ADVISORY BOARD
Palatin works with leading experts who help shape our research and advise on our clinical development programs.
Palatin maintains a Reporting Hotline for reporting suspected violations of our Code of Corporate Conduct and Ethics.